Increased resistance to a farnesyltransferase inhibitor by N-cadherin expression in Bcr/Abl-P190 lymphoblastic leukemia cells.
about
Expression of cassini, a murine gamma-satellite sequence conserved in evolution, is regulated in normal and malignant hematopoietic cellsInterplay of N-Cadherin and matrix metalloproteinase 9 enhances human nasopharyngeal carcinoma cell invasion.Environment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemiaThe regulation of normal and leukemic hematopoietic stem cells by niches.Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia.Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib)Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion frontTargeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy.Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.BM microenvironmental protection of CML cells from imatinib through Stat5/NF-κB signaling and reversal by Wogonin.B-cell precursor acute lymphoblastic leukemia and stromal cells communicate through Galectin-3.Activity of the Aurora kinase inhibitor VX-680 against Bcr/Abl-positive acute lymphoblastic leukemias.Galectin-3 in pre-B acute lymphoblastic leukemia.Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia.Eviction from the sanctuary: Development of targeted therapy against cell adhesion molecules in acute lymphoblastic leukemia.
P2860
Q28710528-5D373856-6918-4DA2-825B-0EB0FF221E7BQ36163116-50F815CF-9A47-4B0C-B5BB-F4FFA3AEF2E6Q36194829-318B9212-35BA-4262-A93F-8410E4BCA53BQ36284911-ED8F5F09-2395-458A-9247-D10961E2939CQ36316166-FCCC0CD6-3806-4EC6-B766-2B88E38E7681Q36373227-2504ED88-32FC-4EB3-95EA-B08A3E8557B9Q36666798-4D54852C-5B73-4341-A186-903085DA23E0Q36848899-6F2D00CE-51ED-46E3-8269-B7A77CB033FAQ37109225-66299175-E86B-4D52-BB84-4D82721755A1Q37109227-2C4C108D-8471-4E6A-80A9-FA45A9F8E7DDQ37269332-EFE0A827-CEB4-428D-96F2-29E30D76DF32Q38887855-1FDB646B-2665-4823-8C47-605D25B5903FQ40491709-281563A8-F04A-465B-B59F-F59F3F892A82Q41891815-39E87E50-84A3-4ACD-AD26-ADB6DA09327AQ42017483-46605A7A-BAB4-4ED2-B940-E4362C065A99Q47783708-B88EBB0D-2B1A-4596-9904-85B45A3546F2
P2860
Increased resistance to a farnesyltransferase inhibitor by N-cadherin expression in Bcr/Abl-P190 lymphoblastic leukemia cells.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Increased resistance to a farn ...... lymphoblastic leukemia cells.
@en
type
label
Increased resistance to a farn ...... lymphoblastic leukemia cells.
@en
prefLabel
Increased resistance to a farn ...... lymphoblastic leukemia cells.
@en
P2093
P2860
P356
P1433
P1476
Increased resistance to a farn ...... lymphoblastic leukemia cells.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.LEU.2404667
P577
2007-03-29T00:00:00Z
P5875
P6179
1031984401